The Board approved a recommendation submitted by the Strategy and Investment for Impact Committee to allow countries to use some of their allocations to fund interventions in response to co-infections that can exacerbate HIV, TB or malaria.

The analysis illustrates important differences in costs of anti-TB medications and highlights potential areas of intervention for initiatives aimed at accelerating progress towards achieving global TB targets, through increasing access to affordable anti-TB medications.

The allocations provided by the Global Fund to countries for 2014-2017 amount to $14.67 billion. The breakdown by type of component is as follows: HIV 52% ($7.64 billion), malaria 29% ($4.26 billion), TB 17% ($2.50 billion) and health systems strengthening 2% ($281 million).

Aidspan in late April published its latest guide: Understanding the New Funding Model, now available for download on the Aidspan website at www.aidspan.org. French, Spanish and Russian editions will be available by 1 June.